Celyad Oncology S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLYYF research report →
About the company
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is CYAD-211, an allogeneic CAR-T therapy based on short hairpin RNA (shRNA), currently undergoing Phase 1 evaluation for relapsed/refractory multiple myeloma.
- CEO
- Michel E. J. Lussier
- IPO
- 2014
- Employees
- 17
- HQ
- Mont-Saint-Guibert, BE
Price Chart
- Market Cap
- $11.19M
- P/E
- 11.41
- P/S
- 500.91
- P/B
- 4.00
- EV/EBITDA
- -1.26
- Div Yield
- 0.00%
- Gross Margin
- 9195.24%
- Op Margin
- -34200.00%
- Net Margin
- 3833.33%
- ROE
- -242.11%
- ROIC
- -289.60%
- Revenue
- $20.99K · -88.71%
- Net Income
- $829.69K · 114.25%
- EPS
- $0.02 · 113.86%
- Op Income
- $-7,179,309
- FCF YoY
- -21.43%
- 52W High
- $0.53
- 52W Low
- $0.15
- 50D MA
- $0.25
- 200D MA
- $0.24
- Beta
- 1.20
- Avg Volume
- 130
Get TickerSpark's AI analysis on CLYYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CLYYF coverage
Recent articles, reports, and earnings notes.
No research on CLYYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLYYF report →Similar companies
Peers in the same neighborhood.